Sec. 3035. Funding for COVID–19 testing, contact tracing, and mitigation activities in congregate settings
351 words·~2 min read·
/bill/117/hr/1319/rh/section-3035·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, $1,800,000,000, to remain available until expended, to carry out activities to detect, diagnose, trace, monitor, and report on SARS–CoV–2 and COVID–19 infections, and related strategies to mitigate the spread of SARS–CoV–2, in congregate settings. From amounts appropriated by subsection (a), the Secretary shall— support activities related to testing through the use of in vitro diagnostic products (as defined in section 809.3(a) of title 21, Code of Federal Regulations) for the detection or diagnosis of SARS–CoV–2 and the virus that causes COVID–19, including to purchase, procure, or administer tests and supplies necessary for administering and processing such tests to staff of, or individuals residing in, congregate settings, and pay (through any mechanism deemed appropriate by the Secretary) part or all of the costs to such entities of administering or processing such tests; support vaccine-related activities for authorized or licensed COVID–19 vaccines, to provide for the vaccination of staff of, or individuals residing in, congregate settings, and pay (through any mechanism deemed appropriate by the Secretary) part or all of the costs to such entities of administering such vaccines; purchase, procure, or distribute personal protective equipment or other products or supplies for use in mitigation of COVID–19 transmission among staff of, or individuals residing in, congregate settings; and provide technical assistance, guidance, and support and award grants, contracts, or cooperative agreements to State, local, territorial, and Tribal public health departments, or Federal, State, local, territorial, or Tribal public and private entities that manage congregate settings, for activities to detect, diagnose, trace, monitor, and report on SARS–CoV–2 and COVID–19 infections, and related strategies and activities to mitigate the spread of SARS–CoV–2, in congregate settings.
For purposes of this section, the term congregate settings includes Federal, State, local, territorial, and Tribal prisons, jails, detention centers (including juvenile detention centers), other correctional, detention, and reentry facilities, long-term care facilities, psychiatric hospitals, psychiatric residential treatment facilities, shared living arrangements for individuals with disabilities, intermediate care facilities, and other residential care facilities.